《大行》花旗升和黄医药(00013.HK)目标价至42元 维持“买入”评级

阿斯达克财经
Jan 03, 2025

和黄医药(00013.HK) 昨日(2日)公布沃瑞沙(ORPATHYS,赛沃替尼/savolitinib)和泰瑞沙(TAGRISSO ,奥希替尼/osimertinib)的联合疗法的新药上市申请已获国家药监局受理并予以优先审评。花旗发表研究报告指,联合疗法相较于同行具有优势,原因包括特定生物标志物MET高,以及口服而且没有化疗的疗程。该行亦提到,公司以6.08亿美元出售其上海和记医药的45%股权,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10